This insider cluster is too small to warrant a trading signal. Monitor for upcoming pipeline catalysts (Septerna is a clinical-stage biotech) and any material 8-K or press release that could move the stock. The director grants are standard compensation and carry no directional implication.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 6 $34.00entry
- T+1 · 4mo ago −1.56%α −2.43% · $33.47
- T+5 · 4mo ago +11.29%α +10.36% · $37.84
- T+20 · 4mo ago +3.47%α +3.89% · $35.18
- T+60 · 7w ago +16.88%α +13.31% · $39.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Septerna insiders (SVP Drug Discovery and Chief People Officer) sold a combined $148K in open-market shares after exercising options. The sales represent ~0.009% of the $1.6B market cap, trivial and consistent with routine tax/vesting-related transactions. No material signal for the stock.
Key Financial Metrics
Key Facts
- Total open-market sales: $148K (0.009% of $1.6B market cap)
- Both sales occurred on the same day as option exercises (tax/vesting pattern)
- 7 directors received non-cash stock grants on 2026-06-26 (no economic value)
- Insider activity is routine and immaterial relative to company size
Financial Impact
Negligible, $148K in insider sales is less than 0.01% of market cap
Risk Factors
- No material risk identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SEPN-1783033258707 |
Track record
24 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20263d ago 144 Neutral 3/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $41.67 +20.39% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $41.30 to $37.68 Now $41.67 +0.90% ▼ −8.77% −8.23% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers